Russia's BIND Therapeutics and Pfizer have signed an agreement for joint development and marketing of new drugs for treating cancers and other diseases. Under the pact, BIND, a biotechnology unit of Rusnano, is to allow the U.S.-based company to use its Accurins technology platform for delivering targeted drugs to cells. The firms then are to share testing of their joint products before the clinical trial stage. The deal involves a Pfizer up-front payment of $50 million as part of a potential $160 million deal for each product that reaches the market. (Click here for more
)
